Viridian Therapeutics had its Relative Strength (RS) Rating upgraded from 74 to 81 Monday.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary rating tracks share price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
History reveals that the best stocks tend to have an RS Rating of over 80 in the early stages of their moves.
Viridian Therapeutics has moved more than 5% past an 18.27 entry in a first-stage consolidation, meaning it's now out of a proper buy zone. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Viridian Therapeutics reported 0% EPS growth last quarter, while sales growth came in at 14%.
Viridian Therapeutics earns the No. 301 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
